The Blood and Marrow Transplant (BMT) Program at Northside Hospital is one of only 20 institutions/consortia from across the United States to be awarded a national grant by the National Heart, Lung and Blood Institute and the National Cancer Institute to recruit, examine and treat clinical study participants.
The grant is the result of Northside’s designation as a Core Clinical Center of the national Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a second consecutive term (July 2010-June 2017, July 2017-June 2024). Northside serves as the lead site of a consortium of core clinical centers that includes the University of Miami and Levine Cancer Institute.
The lead centers selected as the 20 Core Clinical Centers for this new project period are:
- Baylor College of Medicine, Houston, TX
- City of Hope Medical Center, Duarte, CA
- Children’s Hospital, Los Angeles, CA
- Dana-Farber Cancer Institute, Boston, MA
- Duke University, Durham, NC
- Fred Hutchinson Cancer Research Center, Seattle, WA
- H. Lee Moffitt Cancer Center, Tampa, FL
- Mount Sinai School of Medicine, New York, NY
- Johns Hopkins University, Baltimore, MD
- Medical College of Wisconsin, Milwaukee, WI
- Northside Hospital, Atlanta, GA
- The Ohio State University, Columbus, OH
- Oregon Health and Science University, Portland, OR
- Stanford University, Stanford, CA
- Memorial Sloan Kettering Cancer Center, New York,NY
- University of Florida, Gainesville, FL
- University of Michigan, Ann Arbor, MI
- University of Minnesota, Minneapolis, MN
- University of Pennsylvania, Philadelphia, PA
- Washington University, St. Louis, MO
“This recognition is a result of our ongoing excellence and commitment to improving outcomes for hematopoietic stem cell transplant patients,” said Asad Bashey, M.D., Ph.D., medical director of the BMT research program at Northside Hospital and the principle investigator in charge of the hospital’s application to the BMT CTN.
The BMT Program at Northside Hospital is one of the largest and most prominent BMT programs in the United States and performs the entire range of available hematopoietic transplants including those from matched unrelated, matched sibling and haploidentical donors, and cord blood transplants. In 2017, Northside had among the best survival outcomes in nation for a ninth consecutive year (2009-17), per data released by the National Marrow Donor Program and The Center for International Blood and Marrow Transplant Research.
Transplanting healthy marrow may be the best and only hope of a cure for life-threatening diseases such as leukemia, lymphoma and other blood disorders. Clinical Trials are essential to finding new ways of preventing, diagnosing and treating disease.
The BMT CTN is the only federally funded national cooperative clinical trials network charged with conducting multicenter phase III and innovative phase II trials in the field of hematopoietic stem cell transplantation and other forms of cellular therapy. Since 2001, the program has launched 44 trials, accruing nearly 9,500 participants.
Through BMT CTN and other research collaborations, Northside Hospital’s BMT and Leukemia programs offer a comprehensive portfolio of all phases of clinical trials including those with immunotherapy.
For more information about the Blood and Marrow Transplant Clinical Trials Network, visit bmtctn.net.